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Abstract 
 
 
Enzyme cyclooxygenase (COX) inhibition with non-steroidal anti-inflammatory drugs 
(NSAIDs) has long been utilized to treat inflammation and relieve pain. Several studies 
have shown that NSAIDs have also cancer preventative and tumor regressive effects. 
Prostaglandin E2 which acts as an inflammatory mediator influences many mechanisms 
that plays a significant role in tumorigenesis such as cell proliferation, angiogenesis, and 
metastasis. COX overexpression is a characteristic feature of most malignant tumors and 
contributes to poor outcomes in multiple malignancies. It has been reported that cancer 
incidence can be reduced by 25-40% in patients regularly taking low dose COX inhibitor 
aspirin on a daily basis, with the most compelling evidence acquired for colorectal 
cancer. We envisioned that NSAID conjugates derived from 2-alkoxycarbonyl allyl esters 
would have cytotoxicity enhancing prodrug properties with dual anti-inflammatory and 
intracellular alkylation. In the current work, 2-alkoxycarbonyl allyl ester conjugates of 
several common NSAIDs have been synthesized and tested for their cell proliferation 
inhibition properties in breast (MDA-MB-231, 4T1), pancreatic (MIA PaCa-2), and 
colorectal adenocarcinoma (WiDr) cell lines. Several of the synthesized derivatives 
exhibit good potency against all four cancer cell lines. The synthesized compounds have 
also been tested for their COX inhibition properties.  
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CHAPTER 1: INTRODUCTION 
 
NSAIDs have recently been exploited for having a second purpose in the body besides 
anti-inflammatory properties. There are many cancers that are related to chronic inflammatory 
conditions such as the link between inflammatory bowel disease and colon cancer. There is 
strong evidence to suggest that taking an NSAID regularly can help decrease your risk of 
developing colon cancer; and in this regard NSAIDs have been exploited for their potential as 
anticancer agents. 
In 2012, Hanahan and Weinberg identified several distinct hallmarks that lead to tumor 
growth (Figure 1a). Inflammation has been recognized as one of the important markers of 
cancer development and growth and consequently, developing anti-inflammatory agents that are 
specific towards cancer cells will be highly useful towards discovering novel anticancer agents.
4 
 
Figure 1a: Hallmarks of cancer 
When experiencing inflammation, an enzyme called cyclooxygenase (COX) is involved. 
There are two types of COX enzymes, COX-1 and COX-2. COX-1 is present throughout normal 
and cancer cells. It is responsible for many biological pathways such as helping to develop 
stomach lining and making platelets for the removal of clots. The second enzyme, COX-2, is 
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only present when there is an inflammation. It is no surprise that tumors being inflammatory in 
nature also overexpress COX-2 enzyme. Many NSAIDs are not able to distinguish between 
inhibiting COX-1 or COX-2, which is why most NSAIDs have gastrointestinal side effects.  
COX-2 is commonly found in premalignant lesions, carcinoma in situ, invasive cancer, 
and metastatic disease. COX-2 is responsible for forming prostaglandin (PGE2), and this 
upregulation can be found responsible for many different pathways in tumorigenesis including 
immunosuppression, mutagenesis, anti-apoptosis, metastasis, mitogenesis, and angiogenesis 
(Figure 1b).  
 
Figure 1b: Role of COX-2 in cancer development 
 
Some of the commonly used NSAIDs for various pain related ailments are shown in Figure 1c. 
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Figure 1c: Commonly used NSAIDs 
  
 Owing to the importance of cyclooxygenase in cancer progression, there have been several 
synthetic and biological studies for the development of novel NSAID based cyclooxygenase 
inhibitors as anticancer agents. The following are few representative synthetic methods that have 
been reported for the preparation of NSAID based anticancer agents. 
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Metallo derivatives of NSAIDs 
Tabrizi et al. synthesized mefenamic acid potassium salt 2 from NSAID mefenamic acid 
1. The salt was added to a methanolic solution of CdCl2 to provide the complex 
[Cd(mef)2(CH3OH)]n 3 (Scheme 1.1). It exhibited an IC50 value of 0.120.56 µM against MCF-7 
breast cancer cell line and 0.860.21 µM against T-24 bladder cancer cell line.6  
 
Scheme 1.1: Synthesis of mefenamic acid cadmium complexes
6 
 
Scheme 1.2: Synthesis of NSAID triphenyltin(VI) complexes
7 
Coyle et al. reported the reaction of NSAID salicylic acid 5 with silver oxide to form 
dimeric Ag(I) complexes (Scheme 1.3). These derivatives exhibited both antifungal and 
anticancer properties. The complex 6 was tested on squamous carcinoma of tongue Cal-27, 
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hepatocellular carcinoma Hep-G2 and kidney adenocarcinoma A-496 cell lines using an MTT 
assay. The compound exhibited cell proliferation inhibition of 51, 9, and 32 μM respectively.8 
  
Scheme 1.3: Synthesis of dimeric Ag(I) complexes of salicylic acid
8
 
Rodrigo et al. synthesized a diruthenium(I,II)-ketoprofen complex using ketoprofen 7 and 
[Ru2Cl(O2CCH3)4] 8  in the presence of lithium chloride (Scheme 1.4). This complex 9 was 
tested against COX-2 overexpressing HT-29 cell line and Caco-2 cell line with low COX-2 
levels. Cytotoxicity profile of this complex in these two cell lines did exhibit low cell 
proliferation inhibition, signifying that COX-2 inhibition by these drugs did not affect the 
cytotoxicity.
9 
 
 
 
Scheme 1.4: Synthesis of diruthenium(II,III)–ketoprofen complex from ketoprofen9 
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Gust et al. synthesized several [cyclopentadienyl]metalcarbonyl complexes of 
acetylsalicylic acid. Cyclopentadienyl alcohols 10 were prepared by the reaction of 
cyclopentadiene with sodium hydride followed by the addition of alcohol. The alcohol was 
coupled with acetylsalicylic acid chloride in the presence of pyridine to form 
(cyclopentadienyl)alkyl-2-acetoxybenzoate 11. This derivative was further treated with thallium 
ethoxide to obtain η5-[(cyclopentadienyl)alkyl-2-acetoxybenzoate]thallium 12. This complex 
was further functionalized into various metal complexes 13-17 (Scheme 1.5). These complexes 
were evaluated for COX-2 enzyme inhibition, and prop-Cp-ASS-metal complexes 13-17 were 
found to have more inhibitory effects compared to the parent aspirin. The complexes 13-17 were 
also tested for their cytotoxicity in MCF-7 and MDA-MB-231 breast cancer cells and HT-29 
colon cancer cells. 12 exhibited high cytotoxicity in the range of 1.4 to >50 uM in MCF-7, 1.9 to 
>50 uM in MDA-MB-231 and 4.6 to >50 µM in HT-39 cells.
10 
 
7 
 
 
Scheme 1.5: Synthesis of [cyclopentadienyl]metalcarbonyl complexes of acetylsalicylic acid
10
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Non-metallo derivatives of NSAIDS 
Inulin 18 was coupled with ibuprofen 19 in the presence of CDI to synthesize 
nanoparticalized derivative for targeted delivery of epirubicin, an anticancer drug. RGD 
conjugated EPB loaded nanoparticles were then used to encapsulate the inulin-ibuprofen 
polymer 20 (Scheme 1.6). These nanoparticles were tested against BGC832 cell line and were 
found to have relatively non-cytotoxic compared to the parent drug epirubicin. They were also 
evaluated for their anticancer efficacy in H22 xenograft model in male ICR mice and were found 
to have increased tumor growth inhibition compared to free epirubicin.
11 
 
Scheme 1.6: Synthesis of inulin-ibuprofen polymer
11
 
 
 
Babu et al. synthesized mefenamic acid based novel indole analogues starting from 
indole derivatives. Mefenamic acid in 1 was reduced with lithium aluminum hydride followed by 
alkylation with propargyl bromide to give the corresponding alkylated product 21. Treatment of 
21 with o-iodoaniline in the presence of copper catalyst and palladium-carbon provided the 
indolyl mefenamic acid derivative 22 (Scheme 1.7). These compounds were then tested for their 
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anticancer properties on breast cancer cell line MCF-7 to provide an IC50 ranging from 0.75-10 
μM.12 
 
Scheme 1.7: Synthesis of mefenamic acid indole derivatives
12
 
 Rigas et al. synthesized phospho-ibuprofen amides to increase the stability of phopho-
ibuprofen derivatives. Ibuprofen 19 was coupled to 4-aminobutanol in the presence of HBTU 
and diisopropylethylamine (DIPEA) to obtain N-(4-hydroxybutyl)-2-(4-
isobutylphenyl)propenamide 23. This alcohol 23 was converted into phospho-ibuprofen amide 
(PIA) 24 by reacting the alcohol with diethylchlorophosphate in the presence of DIPEA and 
DMAP (Scheme 1.8). This derivative PIA was further nanoparticalized by encapsulating in 
liposomes. This liposome encapsulated PIA was tested against several non-small cell lung 
carcinoma cell lines and it was found to be 10 times more potent than ibuprofen. 
Pharmacokinetic studies of this PIA showed that this form exhibits metabolic stability against 
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hydrolysis with carboxylesterases. Liposome encapsulated PIA also exhibited significant tumor 
growth inhibition compared to ibuprofen in A549 xenograft model.
13 
 
Scheme 1.8: Synthesis of phospho-ibuprofen amides
13
 
 
Zawidlak-Węgrzyńska, et al. synthesized novel conjugates of oligo(3-hydroxybutyrate) 
and ibuprofen. The ibuprofen was made into a sodium salt 25 and then reacted with the oligo(3-
hydroxybutyrate) 26 to give the oligomers of ibuprofen 27. This was further tested for anticancer 
properties on two colon cancer cell lines, HT-29 and HCT 116, using an MTT assay. These IC50 
values ranged from 37-77 µM in the HT-29 line and 31-53µM in the HCT 116 cell line.
14 
 
Scheme 1.9: Sythesis of Ibuprofen Oligo(3-hydroxybutyrate) Derivatives
14
 
Wittine et al. conjugated NSAIDs ibuprofen 19 and ketoprofen 7 with 3-
hydroxypropylamides. Ibuprofen and ketoprofen benzotriazolides 28 and 29 were reacted with 3-
11 
 
hydroxypropylamine in presence of trimethylamine to provide corresponding amide products 30 
and 31 (Scheme 1.10). The compounds were then tested on nine different cell lines (L1200, Molt 
4/C8, CEM, HeLa, MIA PaCa-2, SW 620, MCF-7, H 460, and WI 380). These compounds did 
not exhibit any significant cytotoxic properties and the IC50 values ranged from 55-273 µM in 
cell lines L1200, Molt 4/C8, and CEM.
15
  
 
Scheme 1.10: Synthesis of ketoprofen and ibuprofen 3-hydroxypropylamide derivatives
15
 
 
 
 
  
 
 
Vannini et al. synthesized NOSH-aspirin, a molecule capable of releasing hydrogen 
12 
 
sulfide and nitric oxide intracellularly. 2-hydroxybenzaldehyde 32 was coupled with 4-
bromobutanoic acid in the presence of DCC and catalytic DMAP to obtain bromo derivative 33. 
This bromide undergoes SN2 type reaction with silver nitrate to get the O-nitrated compound 34. 
The aldehyde 34 was oxidized to carboxylic acid using Pinnick oxidation protocol. The 
carboxylic acid 35 was further coupled with ADT-OH to give the desired NOSH-NSAID product 
36 (Scheme 1.11). The compound was shown to have an IC50 of 48 µM on colon cancer line HT-
29 and 57 µM on HCT 15.
16 
Scheme 1.11: Synthesis of NOSH-aspirin derivative
16 
 
 
 
Jacob and Tazawa synthesized an aspirin-glucose derivative by coupling aspirin 37 with 
dimethyl acetal protected glucose 38 using DCC as a coupling agent. The dimethyl acetal 
13 
 
protecting group was deprotected under acidic conditions to give the glucose aspirin conjugate 
39 (Scheme 1.12). This derivative was then tested on three cancer cell lines breast, pancreatic, 
prostate (SKBR3, PC3, PANC-1). The IC50 for this compound ranged from 200-800 µM.
17
  
 
Scheme 1.12: Synthesis of glucose-aspirin conjugate
17 
 
 
 
 
 
 
 
Zhang et al. synthesized cytotoxic podophyllotoxin-NSAID conjugates of aspirin and 
ibuprofen. The carboxylic acid group aspirin 37 or ibuprofen 19 were coupled with hydroxyl 
group in podophyllotoxin 40 with EDC in the presence of DMAP as a catalyst resulting in the 
products 41 and 42 (Scheme 1.13). These derivatives were tested for an IC50 in three cell lines, 
Bel-7402, Bel-7402/5-FU and L-O2. The aspirin derivative had IC50 values of 0.09, 0.065 and 
14 
 
0.19 µM respectively; the ibuprofen podophyllotoxin derivative had IC50 values in the 18.88, 
10.27, and 7.38 µM range.
18
  
 
Scheme 1.13: Synthesis of podophyllotoxin-NSAID derivatives with aspirin and ibuprofen
18 
Chennamaneni et al. synthesized several derivatives of sulindac for the treatment of 
cancer. 2-(5-fluoro-2-methyl-1H-inden- 3-yl)acetic acid 43 was coupled with an amine in the 
presence of  PyBOP and base. The resulting amide 44 was further reacted with an aldehyde in 
the presence of a base to give the target sulindac amides 45 and 46 (Scheme 1.14). The cytotoxic 
effects were tested on HT29 colon cancer cells. The most promising derivatives were the 4-
15 
 
methylsulfinyl derivative 45 and the 4-chloro derivative 46 with IC50 values of 11.3 and 12.4 
μM, respectively.19 
 
Scheme 1.14: Synthesis of sulindac derivatives
19 
Fogli et al. synthesized sulindac hydroxamic acid derivatives to see if substitution of the 
carboxylic acid group for hydroxamic acid could increase the toxicity of the derivative. (O-(tert-
butyl-dimethylsilyl)hydroxylamine) was added to sulindac 47 in the presence of EDC to obtain 
O-silylated hydroxamates 48. Trifluoroacetic acid deprotected the silyl group to give the product 
hydroxamic acid 49. The IC50 values of the derivatives ranged from 32-64 μM against MIA 
PaCa-2 cells, and provided IC50 values ranged from 6-62.5 μM in COLO320 cells.
20
  
16 
 
 
Scheme 1.15: Synthesis of sulindac hydroxamic acid derivatives
20
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Gobec et al. synthesized NSAID analogs for AKR1C3 inhibition. AKR1C3 is a human 
enzyme that belongs to aldo-keto reductase superfamily. This enzyme is responsible for the 
conversion of androstenedione and estrone into testosterone and estrogen, respectively, in 
presence of NADPH cofactor. This enzyme plays a key role in the progression of hormone 
dependent breast and prostate cancers. Various NSAID analogs such as N-acylanthranilic acids, 
2-benzoylbenzoic acids, benzophenones, and phenoxybenzoic acids 50-52 were synthesized and 
evaluated for their activity against human recombinant AKR1C3 (Figure 1d). These analogs 
exhibited IC50 values ranging from 0.68 to 180 µM.
21
  
 
Figure 1d: NSAID analogs for AKR1C3 inhibition
21
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Vela ́zquez et al. synthesized novel NONO-NSAID derivatives using aspirin and 
ibuprofen. The acid chloride 53 and O
2-
acetoxymethyl 1-[N-(2-hydroxyethyl)-N-
methylamino]diazen-1-ium-1,2-diolate 54 were coupled together in triethylamine forming the 
desired product 55. Ibuprofen 19 and O
2-
acetoxymethyl 1-[N-(2-hydroxyethyl)-N-
methylamino]diazen-1-ium-1,2-diolate 54 were coupled together in the presence of DCC and 
trimethylamine to give the product 56. These compounds were tested for their inhibitory activity 
on COX-1 and COX-2 enzymes but did not show any noticeable effects.
22
 
 
Scheme 1.16: Synthesis of NONO-aspirin and NONO-ibuprofen
22
Lu et al. synthesized 
celecoxib based coumarin sulfonamides. Various substituted chalcones were synthesized using 
dimethyl oxalate. These compounds were further coupled with 4-hydrazinylbenzenesulfonamide 
and hydrolyzed to obtain carboxylic acid 57, which was treated with hydrazine hydrate to form 
the amides 58. This was further functionalized to coumarin derivative 59 using POCl3 (Scheme 
1.17). All derivatives were tested against four cancer cell lines (HeLa, HepG2, F10, A549) and 
two non-cancer cell lines (293T, L02). The IC50 values of compounds against HeLa cell lines 
were between 0.36 and 16.19µM and HepG2 cell lines were range from 0.85 to 21.19 μM. All 
compounds also exhibited less toxicity on the non-cancerous cell line than celecoxib.
23
 
19 
 
 
Scheme 1.17: Synthesis of celecoxib based coumarin sulfonamides
23 
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CHAPTER 2: RESULTS AND DISCUSSION 
  
 Baylis-Hillman (BH) reaction is an important C-C bond forming reaction reported in 
organic chemistry. This reaction was originally discovered in the 1970s and it received wide 
attention in the last three decades as evidenced by thousands of scientific publications and 
numerous review articles.
24-28
 This reaction can be easily carried out by simply mixing 
aldehydes/ aldimines/ activated ketones with α, β unsaturated esters, ketones, or nitriles, in the 
presence of a nucleophilic base such as DABCO (Scheme 2.1).
24-28
 This reaction typically does 
not require usage of any solvents, heating, or any special reaction conditions. BH reaction 
provides good reaction yields, with complete atom economy. BH reaction also provides densely 
functionalized allyl alcohols and imines in one step. The product alcohols can be further 
functionalized by converting the alcohol into a leaving group such as an acetate or converting the 
alcohol into allyl bromide, followed by treatment with wide variety of nucleophiles containing C, 
O, S, N atoms etc (Scheme 2.1).
24-28
  
21 
 
 
Scheme 2.1: General scheme of Baylis-Hillman reaction and nucleophilic isomerization 
 
 The allyl bromides 1 and 2 derived from BH alcohols are highly useful synthetic 
intermediates and our group has utilized these bromides for the synthesis of a wide variety of 
medicinally useful natural and synthetic products.
24-28
 The allyl bromides 1 and 2 offer an 
interesting choice of reactive sites for the incoming nucleophiles, involving a direct SN2 attack, 
SN2’ attack with allylic rearrangement, or a simple 1,4-addition to provide functionalized 
synthetic intermediates (Scheme 2.2).  
22 
 
 
Scheme 2.2: SN2, SN2’ and 1,4-addition reactions of Baylis-Hillman bromides 
 
 Our long-standing interest in developing small molecule therapeutics using the BH 
reaction
29
 has prompted us to utilize BH bromide 1 and 2 as a starting material. The bromides 1 
and 2 are highly reactive and based on their structures, these bromides could act as DNA 
alkylating cytotoxic agents. However, these bromides suffer from serious drawbacks such as low 
chemical stability at room temperature, low metabolic stability, and high reactivity with the 
potential for serious side effects. We envisioned that α-carboxycarbonyl allyl esters 3-12 derived 
from carboxylic acids and BH bromides would retain the SN2, or SN2’, or 1,4 addition properties 
with decreased reactivity and improved chemical stability to be developed as potential anticancer 
agents (Scheme 2.3). In this regard, recently, we carried out a study involving the synthesis of α-
carboxycarbonyl allyl esters derived from various carboxylic acids.
29
  
23 
 
 
Scheme 2.3: Synthesis and SN2, SN2’ and 1,4-addition reactions of α-carboxycarbonyl allyl 
esters 
 
 We have evaluated the cell proliferation inhibition studies of the synthesized compounds 
on several cancer cell lines. Our structure-activity relationship (SAR) study indicated that 
aromatic carboxylic compounds in general provided higher cell proliferation inhibition properties 
compared to aliphatic carboxylic acids. Introduction of electron donating or electron 
withdrawing group did not have much effect on the cell proliferation inhibition. Methoxy 
carbonyl group was found to be the optimal structural entity and removal of the double bond 
completely eliminated the biological activity, emphasizing the importance of SN2/SN2’ 
mechanism. The IC50 values of the α-carboxycarbonyl allyl esters 3-12 were found to be in the 
range from 3 -  >100 µM against breast and pancreatic cancer cell lines, MDA-MB-231, 4T1, 
and MiaPaCa-2 (Figure 2.1).  
 
24 
 
 
Figure 2.1: IC50 values of various α-carboxycarbonyl allyl esters 
 
25 
 
 The lead candidate compound 12 upon daily intraperitoneal administration was well 
tolerated in healthy CD-1 mice as evidenced by normal body weight gains compared to vehicle 
treated mice (Figure 2.2A). The lead candidate 12 also exhibited significant tumor growth 
inhibition in a triple negative breast cancer xenograft model MDA-MB-231 (Figure 2.2). 
29
 
 
 
Figure 2.2: A) Systemic toxicity study of 12 in CD-1 mice; B) Anticancer efficacy study of 12 
in MDA-MB-231 tumor xenograft model 
 
As described in the introduction, inflammation has been recognized as one of the 
important tumor markers that can be targeted for anticancer efficacy in many solid tumors. 
Although several NSAIDs have been used as anticancer agents, and/or chemoproventative 
agents, the general lack of cytotoxicity precludes them to be used as primary chemotherapeutic 
26 
 
agents. In the present work, we hypothesize that conjugating the BH bromide with carboxy 
containing NSAIDs would lead to α-carboxycarbonyl allyl esters of NSAIDs with enhanced 
cytotoxic properties. These esters would also release the parent NSAIDs upon interacting with 
intracellular nucleophilic components either in SN2 or SN2’ fashion (Figure 2.3). We envisaged 
that these dual mechanistic properties should provide higher anticancer efficacy than using 
NSAIDs alone.  
 
Figure 2.3: Hypothesis: Conjugates of NSAID carboxylic acids with BH bromides 
 
 With the above hypothesis in mind, initially we chose salicylic acid 13 for conjugating 
with BH bromide 1 derived from formaldehyde. The reaction of salicylic acid 13 with BH 
bromide 1 in the presence of potassium carbonate in DMSO provided methoxycarbonylallyl ester 
15 (Scheme 2.4). The pure 15 could be readily obtained in 89% yield by silica gel column 
chromatography using 2% ethyl acetate in hexanes as eluent. Using the similar protocol, we also 
synthesized carboxycarbonyl allyl ester 16 from acetylsalicylic acid 14 (aspirin) in 90% yield.   
27 
 
 
Scheme 2.4: Synthesis of carboxycarbonyl allyl esters from salicylic acid and aspirin 
 
The carboxy esters 15 and 16 were evaluated against human triple negative breast cancer 
cell line MDA-MB-231 and highly metastatic murine breast cancer cell line 4T1, pancreatic 
cancer cell line MIAPaCa-2 and colorectal adenocarcinoma cell line WiDr. The cell proliferation 
inhibition studies were carried out using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay. MTT is reduced to formazan through mitochondrial 
reductase with an absorbance at 590nm. Cell cultures in 96-well plates were incubated with the 
compounds for 72 h, and MTT values expressed as percent of vehicle-only (control) wells. The 
IC50 value was calculated for each compound as the dose required to suppress the MTT signal to 
50% of control values. These assays were carried out a minimum of three trials and the IC50 
values were calculated using GraphPad Prism 6 Software. Gratifyingly, the IC50 values for 15 
and 16 were found to be in the range from 4 - 17 µM for the above-mentioned cell lines (Figure 
2.4). It is important to note here that the parent NSAIDs salicylic acid 13 and acetylsalicylic acid 
14 did not show any cell proliferation inhibition against any of the cell lines that we used even at 
100 µM concentration. 
28 
 
 
Figure 2.4: IC50 values for carboxycarbonyl allyl esters 15 and 16 
 
Encouraged by significant cell proliferation inhibition at low micromolar concentrations, 
we planned to synthesize and explore the biological properties of several carboxy containing 
NSAIDs. In this regard, we chose six other commercially available NSAIDs, namely ketoprofen 
17, ibuprofen 18, fenamic acid 19, mefenamic acid 20, meclofenamic acid 21 and niflumic acid 
22 (Figure 2.5). Ibuprofen is an over-the-counter NSAID used for pain, ketoprofen is typically 
used for toothaches. Fenamic acid itself is not an NSAID but it is the parent molecule for the 
three NSAIDs mefenamic acid, meclofenamic acid, and niflumic acid. All three of these are 
commonly used for joint or muscle pain as well as pains related to menstruation such as cramps 
or headaches. All these NSAIDs provide the therapeutic benefit by inhibition of COX-1 and 
COX-2. 
29 
 
 
Figure 2.5: Some of the carboxylic acid containing NSAIDs 
  
 Synthesis of carboxycarbonyl allyl esters 23 to 28 involved the similar procedure 
employed in scheme 2.4, by stirring the NSAID carboxylic acids with BH bromide 1 in the 
presence of potassium carbonate in DMSO at room temperature (Scheme 2.5). All the crude 
products were purified by silica gel column chromatography with a mixture of hexanes and ethyl 
acetate as eluents. All the pure products were characterized by 
1
H NMR, 
13
C NMR, and mass 
spectroscopy.  
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Scheme 2.5: Synthesis and IC50 values for carboxycarbonyl allyl esters 23-28 
 
 The cell proliferation inhibition studies were carried out using MTT assay as described 
above. The BH esters derived from aliphatic carboxylic acid NSAIDs ketoprofen and ibuprofen 
23, 24 showed modest cytotoxic properties against all four cancer cell lines. Carboxycarbonyl 
allyl ester of ketoprofen 23 provided IC50 values in the range from 17 µM to >100 µM. 
Carboxycarbonyl allyl ester of ibuprofen 24 exhibited IC50 values in the range from 80 µM to 
>100 µM. These modest cell proliferation inhibition properties are consistent with our earlier 
published work that aliphatic carboxylic acids in general provide less cytotoxic properties than 
aromatic carboxylic acids.
29
 The other aromatic carboxylic acid containing NSAID 
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carboxycarbonyl allyl esters 25-28 showed significant cell proliferation inhibition against all four 
cell lines. Carboxycarbonyl allyl esters of fenamic acid 25, mefenamic acid 26, meclofenamic 
acid 27 and niflumic acid 28 exhibited IC50 values ranged from 16-37 µM, 5-21 µM, 5-21 µM, 
and 15-25 µM, respectively. 
Encouraged by significant increase in cytotoxic values of carboxycarbonyl allyl esters 
23-28 derived from formaldehyde BH bromide 1, we also synthesized carboxycarbonyl allyl 
esters 29-32 using benzaldehyde BH bromide 2 and NSAIDs 13, 14, 17 and 18. The 
corresponding BH bromide 2 was synthesized in two steps starting from benzaldehyde which 
upon condensation with methyl acrylate in the presence of DABCO provided the BH alcohol, 
which was then brominated using HBr and H2SO4. The bromide 2 upon reaction with NSAIDs 
13, 14, 17 and 18 in the presence of potassium carbonate in DMSO provided the crude esters 29-
32 (Scheme 2.6). The pure products were readily obtained using silica gel chromatography using 
a mixture of hexane and ethyl acetate as eluents. All the synthesized products were characterized 
by 
1
H NMR, 
13
C, and mass spectrometry. 
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Scheme 2.6: Synthesis of benzaldehyde BH ester 2 and the corresponding NSAID esters 29-32 
 
MTT based cell proliferation inhibition properties against two breast cancer cell lines, 
MDA-MB-231 and 4T1 of carboxycarbonyl esters 29-32 exhibited slightly decreased IC50 values 
compared to carboxycarbonyl allyl esters 23-28 derived from formaldehyde BH bromide 1. 
Again, the aromatic carboxycarbonyl allyl esters of NSAIDs salicylic acid 29 and acetylsalicylic 
acid 30 provided higher cell proliferation inhibition than aliphatic carboxycarbonyl allyl esters of 
ketoprofen 31 and ibuprofen 32. Owing to the decreased cell proliferation inhibition properties 
and lower water solubility, we did not synthesize carboxycarbonyl allyl esters from the NSAIDs 
19-22. From this SAR study, it is quite evident that β-unsubstitution is more preferred than β-
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substitution in the double bond region. These results also provide credence for our hypothesis 
that SN2’ mechanism may be operative in providing the biological activity.  
 Since our proposed mechanism for enhanced cell proliferation property involves the 
double bond for SN2, SN2’ and 1,4 addition, we sought to understand its critical role by saturating 
the double bond. For this purpose, we chose dihydroxylation of double bond in 
carboxycarbonylallyl esters 15, 16, 23-28. These allyl esters were treated with a catalytic amount 
of osmium tetroxide in the presence of N-methylmorphiline N-oxide in acetone to afford the 
crude diols 33-40 (Scheme 2.7). The crude compounds were purified by silica gel column 
chromatography by using hexane and ethyl acetate (1:1) as eluents to obtain pure products in 65 - 
78% yield. 
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Scheme 2.7: General scheme for dihydroxylation of carboxycarbonyl allyl esters  
Cell proliferation studies using MTT assay indicated that none of these diolic 
carboxycarbonyl esters 33-40 did not exhibit any significant inhibition even at 100 µM 
concentration against all four cancer cell lines. These results are not surprising as we have 
observed similar loss of activity in the case of simple carboxylic acids in our earlier work.
29
  
As a part of SAR study, we synthesized a simple allyl ester 41 from salicylic acid 13 
which has limited capability of SN2 or SN2’. Reaction of salicylic acid with allyl bromide under 
basic conditions provided the corresponding allyl ester 41 in 71% yield (Scheme 2.8). As 
expected, the biological evaluation of 41 against two breast cancer cell lines, MDA-MB-231 and 
4T1 indicated no cell proliferation inhibition properties even at 100 µM concentration. The loss 
of cytotoxic activity also reaffirms the critical role of the double bond with α-carboxycarbonyl 
group in providing the biological activity via SN2, SN2’, and 1,4 addition pathways. 
 
Scheme 2.8: Synthesis of salicylic acid allyl ester 41 
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Conclusion and Future Directions 
In conclusion, we have synthesized, purified, and characterized several new compounds 
based on various commercially available NSAIDs. All the synthesized compounds were 
evaluated for cell proliferation inhibition using MTT assay against four cancer cell lines, MDA-
MB-231, 4T1, MiaPaCa-2, and WiDr. All the 2-alkoxycarbonyl allyl esters conjugates of 
NSAIDs exhibited significantly higher cell proliferation inhibition than the parent NSAIDs. In 
general, β-unsubstitution in the double bond provided higher biological activity than β-
substituted derivatives. Aromatic carboxylic acid containing NSAID esters of BH bromides 
exhibited higher cell proliferation inhibition than aliphatic carboxylic acid containing NSAIDs. 
Structure activity relationship studies also indicated that double bond in 2-alkoxycarbonyl allyl 
ester was a critical component for cell proliferation inhibition, and saturation of the double bond 
resulted in complete loss of activity, confirming that SN2/SN2’ mechanism plays a key role in 
providing the biological activity. Based on the higher cell proliferation inhibition properties, four 
carboxycarbonylallyl esters derived from salicylic acid, acetyl salicylic acid, mefenamic acid and 
meclofenamic acid were designated as lead candidate compounds for further studies. 
The future directions of this project will involve evaluation of COX inhibition of all the 
lead compounds and identification of primary lead candidate compound that exhibits higher cell 
proliferation inhibition, and COX inhibition. The primary lead will also be evaluated for 
systemic toxicity study in healthy CD-1 mice and anticancer efficacy studies in mice tumor 
models using WiDr colorectal adenocarcinoma cell line and pancreatic cancer cell line MiaPaCa-
2. 
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CHAPTER 3: Experimental Procedures and Spectral Characterization 
 
General procedure for the synthesis of 2-(bromomethyl)acrylate-NSAIDs  
A mixture of NSAID (1.0 eq, 42.7 mmol) and methyl 2-(bromomethyl)acrylate 
(1.1 eq, 46.9 mmol) in 30ml DMSO were first stirred at room temperature for 30 minutes, 
followed by the addition of potassium carbonate (3.0 eq, 128 mmol). The reaction mixture was 
stirred for 1 hour at rt. After it was confirmed that the reaction was completed using a TLC (10% 
EtOAc/hexane), water was added to the reaction mixture in order to dissolve the excess 
potassium carbonate, and extracted with three times diethyl ether. The crude product was 
purified by silica gel column chromatography using hexanes and ethyl acetate as eluents.  
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2-(methoxycarbonyl)allyl 2-hydroxybenzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 10.61 (s, 1H), 7.83 (dd, J = 2.0, 4.5 Hz, 1H), 7.43 (m, 1H), 6.94 (dd, J =1, 8.5  Hz, 1H), 6.84 
(m, 1H), 6.41 (s, 1H), 5.93 (s, 1H), 5.05 (s, 2H), 3.78 (s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 169.40, 165.38, 161.73, 135.89, 134.77, 129.83, 127.98, 119.20, 117.61, 112.12, 62.99, 52.09 
HRMS (ESI) m/z: calc’d for C12H12O5 [M+Na]
+
 : 259.0577, found 259.0777 
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2-(methoxycarbonyl)allyl 2-acetoxybenzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 8.04 (dd, J =1.5, 8 Hz, 1H), 7.57 (m, 1H), 7.32 (m, 1H), 7.11 (dd, J = 1.5, 8.5Mz, 1H), 6.42 (s, 
1H), 5.93 (s, 1H), 5.02 (s, 2H), 3.80 (s, 3H), 2.32 (s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 169.64, 165.59, 163.81, 150.78, 135.03, 134.08, 131.81, 127.9, 126.06, 123.89, 122.96, 63.00, 
52.09, 20.98 
HRMS (ESI) m/z: calc’d for C14H14O6 [M+Na]
+
 : 301.0683, found 301.0906 
 
  
39 
 
 
3-methoxy-2-oxobut-3-en-1-yl 2-(4-isobutylphenyl)propanoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 7.21 (d, J = 8.0 Hz, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.22 (s, 1H), 5.54 (s, 1H), 4.81 (dd, J = 14.0, 
50 Hz, 2H), 3.76 (q, J = 7.0 Hz, 2H), 3.71 (s, 3H), 2.45 (d, J = 7.0 Hz, 2H), 1.87-1.82 (m, 1H), 
1.51 (d, J = 7.0 Hz, 3H), 0.89 (d, J = 6.5 Hz, 6H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 173.95, 165.54, 140.65, 137.46, 135.18, 129.33, 127.21, 126.76, 62.31, 51.88, 45.07, 45.00, 
30.18, 22.33, 18.24 
HRMS (ESI) m/z: calc’d for C18H24O4 [M+Na]
+
 : 327.1567, found 327.1789 
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methyl 2-(((2-(3-benzoylphenyl)propanoyl)oxy)methyl)acrylate 
 
1
H NMR (500 MHz, CDCl3): 
δ 7.79-7.4 (m, 8H), 6.26 (s, 1H), 5.64 (s, 1H), 4.80 (dd, J = 14.5, 23 Hz, 2H), 3.81 (q, J = 7.0 Hz, 
1H), 3.70 (s, 3H), 1.55 (d, J = 7.0 Hz, 3H) 
 
13
C NMR (125 MHz, CDCl3): 
δ 196.36, 173.32, 165.46, 140.55, 137.95, 137.44, 135.02, 132.51, 131.49, 130.03, 129.20, 
129.07, 128.55, 128.31, 127.34, 62.73, 51.97, 45.31, 18.29 
HRMS (ESI) m/z: calc’d for C21H12O5 [M+Na]
+
 : 375.1203, found 375.1433 
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2-(methoxycarbonyl)allyl 2-(phenylamino)benzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 9.42 (s, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.36-7.24 (m, 7H), 7.10 (t, J = 7.5 Hz, 1H), 6.74 (t, J = 
7.0 Hz, 1H), 6.43 (s, 1H), 5.97 (s, 1H), 5.06 (s, 2H), 3.82 (s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 167.72, 165.70, 148.22, 140.62, 135.71, 134.37, 131.60, 129.38, 127.43, 123.70, 122.64, 
117.21, 114.05, 111.48, 62.45, 52.11 
HRMS (ESI) m/z: calc’d for C18H17NO4 [M+Na]
+
 : 334.105, found 334.127 
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2-(methoxycarbonyl)allyl 2-((2,3-dimethylphenyl)amino)benzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 9.21 (s, 1H), 8.00 (d, J = 10.0 Hz, 1H), 7.26-6.67 (m, 7H), 6.44 (s, 1H), 5.99 (s, 1H), 5.08 (s, 
2H), 3.83 (s, 3H), 2.34 (s, 3H), 2.18 (s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 167.89, 165.73, 149.71, 138.59, 138.23, 135.44, 134.41, 132.54, 131.42, 127.27, 126.88, 
125.95, 123.19, 116.08, 113.73, 110.37, 62.31, 52.09, 20.62, 14.00 
HRMS (ESI) m/z: calc’d for C20H21NO2 [M+Na]
+
 : 362.1363, found 362.1603 
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2-(methoxycarbonyl)allyl 2-((2,6-dichloro-3-methylphenyl)amino)benzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 9.28 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.32-7.26 (m, 2H), 7.12 (d, J = 8.5 Hz, 1H), 6.77 (t, J = 
8.0 Hz, 1H), 6.45 (s, 1H), 6.33 (d, J = 8.5 Hz, 1H), 6.00 (s, 1H), 5.09 (s, 2H), 3.83 (s, 3H), 2.42 
(s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 167.75, 165.73, 147.73, 136.49, 135.33, 135.08, 134.34, 134.22, 131.31, 131.28, 128.59, 
127.73, 127.51, 117.37, 113.79, 111.26, 62.51, 52.09, 20.63  
HRMS (ESI) m/z: calc’d for C19H17 Cl2NO4 [M+Na]
+
 : 416.0427, found 416.0687 
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2-(methoxycarbonyl)allyl 2-((3-(trifluoromethyl)phenyl)amino)nicotinate 
 
1
H NMR (500 MHz, CDCl3):  
δ 10.28 (s, 1H), 8.42 (d, J = 7.0 Hz, 1H), 8.29 (d, J = 10.0 Hz, 1H), 8.09 (s, 1H), 7.88 (d, J = 8.5 
Hz, 1H), 7.43 (t, J = 16.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 6.80 (m, 1H), 6.46 (s, 1H), 5.97 (s, 
1H), 5.09 (s, 2H), 3.83 (s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 166.79, 165.52, 155.78, 153.32, 140.26, 134.89, 131.12(quartet), 129.18, 128.31, 125.26, 
123.55, 123.09, 119.10, 117.16, 114.10, 107.13, 63.23, 52.17 
HRMS (ESI) m/z: calc’d for C18H15F3N2O4 [M+Na]
+
 : 403.0876 found 403.1146 
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Synthesis of Benzaldehyde Baylis Hillman Compounds 
 
(E)-2-(methoxycarbonyl)-3-phenylallyl 2-hydroxybenzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 10.71 (s, 1H), 8.10 (s, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.37 (m, 6H), 7.00 (d, J = 8.5 Hz, 1H), 
6.87 (t, J = 8.0 Hz, 1H), 5.23 (s, 2H), 3.87 (s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 169.76, 167.51, 161.68, 146.40, 135.82, 134.06, 130.06, 129.81, 129.43, 128.98, 126.01, 
119.21, 117.60, 112.33, 60.09, 52.43 
HRMS (ESI) m/z: calc’d for C18H16O5 [M+Na]
+
 : 335.089, found 335.1116 
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(E)-2-(methoxycarbonyl)-3-phenylallyl 2-acetoxybenzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 8.07 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.57 (m, 1H), 7.42 (m, 5H), 7.32 (t, J = 7.5 Hz, 1H), 7.11 
(d, J = 8.5 Hz, 1H), 5.16 (s, 2H), 3.86 (s, 3H), 2.29 (s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 169.61, 167.28, 164.22, 150.75, 146.13, 134.06, 134.01, 132.04, 129.74, 129.52, 128.87, 
126.40, 126.07, 123.90, 123.13, 60.07, 52.39, 20.92 
HRMS (ESI) m/z: calc’d for C20H18O6 [M+Na]
+
 : 377.0996, found 377.1254 
 
 
methyl (E)-2-(((2-(3-benzoylphenyl)propanoyl)oxy)methyl)-3-phenylacrylate 
 
1
H NMR (500 MHz, CDCl3):  
δ 7.96 (s, 1H), 7.76-7.20 (m, 14H), 5.00 (d, J = 12.0 Hz, 1H), 4.85 (dd, J =12, 73 Hz, 1H), 3.87 
(q, J=7 Hz, 1H), 3.78 (s, 3H), 1.56 (d, J = 7.5 Hz, 3H) 
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13
C NMR (125 MHz, CDCl3):  
δ 196.39, 173.64, 167.81, 145.80, 140.72, 137.98, 137.46, 134.04, 132.49, 131.50, 130.03, 
129.58, 129.33, 129.02, 128.65, 128.55, 128.30, 126.35, 59.83, 52.23, 45.34, 18.18 
HRMS (ESI) m/z: calc’d for C27H24O5 [M+Na]
+
 : 451.1516, found 451.1825 
 
 
 
methyl (E)-2-(((2-(4-isobutylphenyl)propanoyl)oxy)methyl)-3-phenylacrylate 
 
1
H NMR (500 MHz, CDCl3):  
δ 7.87 (s, 1H), 7.22-7.02 (m, 9H), 4.80 (dd, J = 11.5, 94 Hz, 1H), 3.67 (s, 3H), 2.37 (d, J = 7.0 
Hz, 2H), 1.76 (m, 1H), 1.43 (d, J = 7.0 Hz, 3H), 0.81 (m, 6H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 174.35, 167.31, 145.83, 140.56, 137.65, 134.10, 129.44, 129.39, 128.58, 127.55, 126.52, 59.63, 
52.17, 45.07, 45.04, 40.93, 30.20, 22.39, 22.37, 18.27 
HRMS (ESI) m/z: calc’d for C24H28O4 [M+Na]
+
 : 403.188, found 403.2148 
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allyl 2-hydroxybenzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 10.71 (s, 1H), 7.85 (s, 1H), 7.42 (s, 1H), 6.95 (s, 1H), 6.85 (s, 1H), 6.00 (m, 1H), 5.40 (d, J = 
17.0 Hz, 1H), 5.29 (d, J = 5.5 Hz), 4.81 (s, 2H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 169.80, 161.72, 135.75, 131.58, 129.92, 119.15, 118.88, 117.59, 112.38, 65.79 
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Synthesis of Baylis Hillman NSAID Diols 
To compound (2 mmol) in acetone (10 mL) was added N-methylmorpholine-N-oxide (NMO) (5 
mmol) and catalytic osmium tetroxide (0.02 mmol).  Reaction was stirred at room temperature 
for an hour. Upon completion (TLC), acetone was removed under reduced pressure and residue 
obtained was diluted with 50 mL of water and the crude product was extracted with ethyl acetate 
(3x25mL) and purified via column chromatography (1:5, EtOAc:Hexanes) to obtain the diol 
(70%). 
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2-hydroxy-2-(hydroxymethyl)-3-methoxy-3-oxopropyl 2-acetoxybenzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 7.99 (d, J = 8.0 Hz, 1H), 7.63 (t, J = 7.5 Hz, 1H), 7.36 (t, J = 7.5 Hz, 1H) 7.16 (d, J = 8.0 Hz, 
1H), 4.50 (s, 2H), 3.93-3.81 (m, 7H), 2.40 (s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 173.02, 169.85, 163.71, 150.91, 134.29, 131.62, 126.11, 123.89, 122.41, 77.62, 66.13, 64.71, 
53.45, 21.00 
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2-hydroxy-2-(hydroxymethyl)-3-methoxy-3-oxopropyl 2-hydroxybenzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 10.47 (s, 1H), 7.74 (d, J = 10.0 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.87 
(t, J = 15.0 Hz, 1H), 4.51 (dd, J = 11.5, 21.0 Hz, 2H), 3.92-3.80 (m, 7H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 172.97, 169.40, 161.68, 136.18, 129.82, 119.40, 117.69, 111.77, 110.00, 66.27, 64.68, 53.64 
HRMS (ESI) m/z: calc’d for C12H14O7 [M+Na]
+
 : 293.0632, found 293.0848 
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methyl 2,3-dihydroxy-2-(((2-(4-isobutylphenyl)propanoyl)oxy)methyl)propanoate 
[DIASTEREOMERS] (1:1) 
 
1
H NMR (500 MHz, CDCl3):  
δ 7.18-7.08 (m, 8H), 4.26-4.16 (m, 4H), 3.77-3.64 (m, 14H), 2.55-2.43 (m, 6H), 1.88-1.80 (m, 
2H), 1.47 (t, J=7 Hz, 6H), 0.89 (d, J = 7.5 Hz, 12H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 174.19, 172.87, 172.75, 140.75, 140.69, 137.27, 137.11, 129.33, 127.20, 127.17, 66.04, 65.80, 
64.62, 64.55, 45.00, 44.98, 44.83, 30.17, 22.33, 18.13, 18.08 
 
HRMS (ESI) m/z: calc’d for C18H26O6 [M+Na]
+
 : 361.1622, found 361.1898 
 
  
53 
 
 
methyl 3-((2-(3-benzoylphenyl)propanoyl)oxy)-2-hydroxy-2-(hydroxymethyl)propanoate 
[DIASTEREOMERS] (1:1) 
 
1
H NMR (500 MHz, CDCl3):  
δ 7.81 (m, 9H), 4.33-4.21 (m, 2H), 3.85-3.62 (m, 8H), 1.53 (m, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 196.52, 196.48, 173.42, 173.39, 172.78, 172.71, 140.42, 140.33, 138.04, 137.99, 137.36, 
132.61, 132.59, 131.52, 131.46, 130.10, 130.09, 129.23, 129.17, 129.11, 128.51, 128.47, 128.33, 
66.07, 65.91, 64.59, 64.57, 60.40, 53.32, 53.23, 45.22, 45.19, 21.03, 18.13, 18.11, 14.18 
HRMS (ESI) m/z: calc’d for C21H22O7 [M+Na]
+
 : 409.1258,  found 409.1557 
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2-hydroxy-2-(hydroxymethyl)-3-methoxy-3-oxopropyl 2-(phenylamino)benzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 9.32 (s, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.36-7.11 (m, 9H), 6.73 (t, J = 7.0 Hz, 1H), 4.48 (dd, J = 
10.5, 32 Hz, 2H), 3.94-3.82 (m, 7H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 173.22, 167.72, 148.30, 140.47, 134.57, 131.54, 129.39, 123.85, 122.78, 117.20, 114.05, 
110.96, 65.88, 64.74, 53.55 
HRMS (ESI) m/z: calc’d for C18H19NO6 [M+Na]
+
 : 368.1105, found 368.1375 
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2-hydroxy-2-(hydroxymethyl)-3-methoxy-3-oxopropyl2-((2,3-dimethylphenyl)amino) benzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 9.12 (s, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.27-7.04 (m, 4H), 6.73 (d, J = 8.5 Hz, 1H), 6.66 (t, J = 
8.0 Hz, 1H), 4.49 (dd, J = 9.5, 30 Hz, 2H), 3.95-3.82 (m, 7H), 2.33 (s, 3H), 2.17 (s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 173.26, 167.95, 149.81, 138.45, 138.27, 134.65, 132.64, 131.38, 127.03, 125.99, 123.34, 
116.17, 113.71, 109.80, 77.72, 65.87, 64.75, 53.52, 20.61, 13.99 
HRMS (ESI) m/z: calc’d for C20H23NO6 [M+Na]
+
 : 396.1418, found 396.1702 
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2-hydroxy-2-(hydroxymethyl)-3-methoxy-3-oxopropyl2-((2,6-dichloro-3-methylphenyl) 
amino)benzoate 
 
1
H NMR (500 MHz, CDCl3):  
δ 9.18 (s, 1H), 7.90 (d, 1H), 7.32-7.26 (m, 2H), 7.12 (d, J=12.5Hz, 1H), 6.75 (t, J= 7.5 1H), 6.31 
(d, J= 8.5 1H), 4.53 (dd, J=12Hz, J=17 Hz, 1H), 3.86-3.72 (m, 5H), 2.40 (s, 3H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 173.26, 167.77, 147.82, 136.52, 134.94, 134.48, 134.36, 131.31, 128.71,  127.75, 117.49, 
113.78, 110.71, 77.64, 66.00, 64.75, 53.57, 53.55 20.61 
HRMS (ESI) m/z: calc’d for C19H19Cl2NO6 [M+Na]
+
 : 450.0482, found 450.0799 
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2-hydroxy-2-(hydroxymethyl)-3-methoxy-3-oxopropyl2-((3-(trifluoromethyl)phenyl) 
amino)nicotinate 
 
1
H NMR (500 MHz, CDCl3):  
δ 10.18 (s, 1H), 8.50 (d, J = 5.0 Hz, 1H), 8.24 (d, J = 8.0 Hz, 1H), 8.14 (s, 1H), 7.92 (d, J = 8.5 
Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 6.87 (m, 1H), 4.59 (dd, J = 11.0, 39.5 
Hz, 2H), 4.01-3.89 (m, 6H) 
 
13
C NMR (125 MHz, CDCl3):  
δ 173.06, 166.74, 155.79, 153.58, 140.26, 140.07, 132.04 (quartet), 129.23, 123.73, 119.32, 
119.29, 117.37, 114.21, 106.68, 66.30, 64.71, 53.69 
 
HRMS (ESI) m/z: calc’d for C18H17F3N2O6 [M+H]
+
 : 415.1111, found 415.1395 
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Biological Evaluation  
  
Table 1: IC50* values of NSAID-Baylis Hillman derivatives in MiaPaCa-2, MDA-MB-231, 
4T1, and WiDr cell lines using MTT assay 
 
Compound MiaPaCa-2 MDA-MB-
231 
4T1 WiDr 
Salicylic Acid Baylis Hillman 
  
15±1 17±2 11±2 4±1 
Aspirin Baylis Hillman
 
14±3 13±2 12±3 4±1 
Ketoprofen Baylis Hillman 
 
95±5 54±6 >100 17±0 
Ibuprofen Baylis Hillman 
 
>100 >100 >100 80±5 
Fenamic Baylis Hillman 36±2 26±3 37±1 16±2 
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Mefenamic Acid Baylis 
Hillman  
7±1 9±1 16±1 6±1 
Meclofenamic Acid Baylis 
Hillman  
7±2 10±3 21±1 5±1 
Niflumic Acid Baylis Hillman 
 
25±1 22±1 24±2 15±1 
Salicyic Acid Baylis Hillman 
Diol  
>100 >100 >100 >100 
Aspirin Baylis Hillman Diol 
 
>100 >100 >100 >100 
Ketoprofen Baylis Hillman >100 >100 >100 >100 
60 
 
Diol  
Ibuprofen Baylis Hillman Diol 
 
>100 >100 >100 >100 
Fenamic Acid Baylis Hillman 
Diol  
>100 >100 >100 >100 
Mefenamic Acid Baylis 
Hillman Diol 
 
>100 >100 >100 >100 
Meclofenamic Acid Baylis 
Hillman Diol 
 
>100 >100 >100 >100 
Niflumic Acid Baylis Hillman >100 >100 >100 >100 
61 
 
Diol  
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